United Kingdom · Question · Written question
HL HL4681
Respiratory Syncytial Virus: Vaccination
Introduced
11 January 2023
Last action
17 January 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 January 2023
Summary
To ask His Majesty's Government what steps the Joint Committee on Vaccination and Immunisation (JVCI) will take to examine all Respiratory Syncytial Virus (RSV) technologies before deciding to offer Nirsevimab to newborn babies.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
11 January 2023
Written question
To ask His Majesty's Government what steps the Joint Committee on Vaccination and Immunisation (JVCI) will take to examine all Respiratory Syncytial Virus (RSV) technologies before deciding to offer Nirsevimab to newborn babies.
Source: Lords
17 January 2023
Answer
The Joint Committee on Vaccination and Immunisation (JCVI) respiratory syncytial virus (RSV) subcommittee is expecting, over a series of meetings, to consider the range of products that are in later stages of development aimed at preventing RSV in young c...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-01-11/HL4681
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1566212
- uk · wq-1566212 · source updated 17 January 2023